Clinical trial
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
NCT00090610 · Duke University, Other · Completed
Key facts
| NCT number | NCT00090610 |
|---|---|
| Title | Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer |
| Official title | Multicenter, Randomized, Phase II Comparative Study to Compare Efficacy & Safety of Taxotere®/Carboplatin Combination Therapy vs Sequential Therapy w/ Taxotere® Then Carboplatin as Second-line Treatment of Patients w/ Relapsed, Platinum-sensitive Ovarian Cancer |
| Lead sponsor | Duke University, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Carboplatin |
| Enrollment | 150 |
| Start date | Oct 1, 2003 |
| Primary completion | Mar 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Aug 31, 2004 |
| Last update posted | Feb 25, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: